Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitor

This page shows the latest PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Roche – which is already an emerging player in immuno-oncology with its Tecentriq (atezolizumab) PD-L1 inhibitor and a pipeline of new candidates – says it wants to use the technology across

Latest news

  • FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

    Three years ago it joined forces with Bristol-Myers Squib b to test it alongside BMS’PD-1 inhibitor Opdivo (nivolumab) in solid tumours, and has also looked into pairing the ... drug with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) and

  • New cancer drugs can’t quite plug the revenue hole at AZ New cancer drugs can’t quite plug the revenue hole at AZ

    There was also a welcome surge in of PD-L1 inhibitor Imfinzi to $184m – $122m of that coming in the second quarter – coming mainly from the drug’s recent approval in ... cancer. The MEK inhibitor had previously failed in a late-stage lung cancer

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    Rochester, Minnesota-based Vyriad – which spun out of the Mayo Clinic – will contribute its lead drug candidate Voyager-V1 to a trial in which it will be paired with PD-L1 ... others. Meanwhile, for Merck and Pfizer the deal adds another combination

  • Pivotal data sets up Tecentriq filing in small cell lung cancer Pivotal data sets up Tecentriq filing in small cell lung cancer

    Roche’s PD-L1 inhibitor Tecentriq has become the first cancer immunotherapy to improve survival in extensive-stage small cell lung cancer (ES-SCLC), putting it on course to end a ... The company says it will press ahead with regulatory filings in the US

  • BMS presses go on Nektar combo pivotal trials, despite data debate BMS presses go on Nektar combo pivotal trials, despite data debate

    In fact, they have data which suggests NKTR-214 can actually make PD-L1-negative tumours start expressing the biomarker. ... For BMS, the partnership with Nektar is part of an attempt to rebuild momentum behind Opdivo, which is still the biggest-selling

More from news
Approximately 4 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... This deal gives Pfizer co-development and co-marketing rights to MSB0010718C, Merck KGaA's anti-PD-L1

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics